Natural Desiccated Thyroid (Armour, NP Thyroid): What the Evidence Says

Natural desiccated thyroid (Armour, NP Thyroid) contains porcine T4 and T3 in a fixed ratio. Some patients report feeling better on it, but randomized trials have not shown consistent benefit over levothyroxine on objective outcomes. The American Thyroid Association does not recommend it first-line. Switching requires careful monitoring of TSH, free T4, and free T3.

What natural desiccated thyroid actually is

Natural desiccated thyroid (NDT) — sold as Armour Thyroid, NP Thyroid, and a few smaller-volume brands — is a powdered extract of pig (porcine) thyroid glands, standardized by total iodine content and packaged in grain-based doses (1 grain ≈ 60–65 mg of extract, delivering roughly 38 mcg T4 and 9 mcg T3) [C1][C4]. Because it is a whole-gland extract, it contains both prohormones (T4 and T3) plus thyroglobulin and small amounts of T1 and T2 [C1].

The T4-to-T3 ratio in NDT is fixed at roughly 4:1 by weight. The human thyroid gland secretes a much higher ratio — closer to 14:1 — and most circulating T3 in healthy people is generated by peripheral deiodinase conversion from T4 rather than by direct thyroid release [C1][C4]. This is the central pharmacologic argument the ATA makes against NDT as a physiologic replacement: the T3 dose delivered with each tablet is supraphysiologic relative to what a healthy gland releases [C1].

NDT also has more batch-to-batch variability than synthetic levothyroxine. The FDA monograph allows ±10% variation in T4 and T3 content per tablet, and historical recalls (most recently NP Thyroid in 2020) have flagged sub-potent batches [C4]. Synthetic levothyroxine, by contrast, has tighter potency specifications and a stable single-hormone profile [C1].

What randomized trials actually show

Three RCTs anchor what we know about NDT versus levothyroxine on objective outcomes:

• Hoang 2013 (crossover RCT, n=70): Patients were randomized to NDT or levothyroxine for 16 weeks, then crossed over. Mean weight loss was modestly greater on NDT (about 1.5 kg), and TSH was higher on NDT, but there was no difference in quality-of-life scores or neurocognitive performance. Importantly, 48.6% of patients preferred NDT, 18.6% preferred levothyroxine, and 32.9% had no preference — but objective measures did not match the preference signal [C2].
• Shakir 2021 (RCT, n=75): Three-arm trial comparing levothyroxine, desiccated thyroid extract, and LT4+LT3 combination. All three groups achieved similar TSH targets. No significant difference in symptom scores or quality of life between arms when TSH was matched [C3].
• LT4/LT3 consensus 2021: The joint American/European/British thyroid society review concluded that current evidence does not support routine use of NDT or LT4+LT3 combinations over levothyroxine, while acknowledging a small subset of patients may benefit from a trial of combination therapy under specialist supervision [C4].

The signal across these trials is consistent: on average, NDT does not outperform levothyroxine on objective measures, but a subset of patients reports a preference for it [C2][C3][C4]. Whether that preference reflects unmeasured biological benefit, the supraphysiologic T3 hit (which can feel stimulating in the hours after a dose), placebo, or expectation effects is not resolved [C4].

Where NDT may have a role

The ATA and the 2021 consensus both leave open a narrow window: patients who remain symptomatic on adequate levothyroxine monotherapy — with TSH in the normal range and no other reversible cause — may reasonably try a combination approach (NDT or LT4+LT3) under specialist supervision [C1][C4]. This is a small minority of hypothyroid patients, and the trial period is typically 3 to 6 months with predefined success criteria [C4].

Risks of NDT, especially the T3 component

The main safety concerns with NDT trace to the T3 dose. T3 has a short half-life (around 24 hours) and produces a sharp post-dose serum peak, in contrast to levothyroxine's slow, steady release [C1][C5].

• Cardiac risk. A 2025 systematic review and meta-analysis of liothyronine-containing regimens (including NDT and LT4+LT3) found a signal toward increased atrial arrhythmia risk in some cohorts, particularly older patients and those with pre-existing heart disease [C5]. Levothyroxine over-replacement (suppressed TSH below 0.1 mIU/L) carries similar cardiac risk [C6].
• Bone density. Persistently low TSH from any thyroid hormone over-replacement is associated with reduced bone density and fracture risk in postmenopausal women [C1][C6].
• Symptom variability. Some patients report palpitations, anxiety, insomnia, or jitteriness in the hours after an NDT dose — the T3 peak [C2][C5].
• Batch variability. Sub-potent or super-potent batches can swing TSH unpredictably, requiring more frequent lab checks than levothyroxine [C4].
• Not for pregnancy. NDT is not recommended in pregnancy. T4 crosses the placenta and supports fetal brain development; T3 does not. Pregnant patients on NDT are switched to levothyroxine [C1][C7].

What does NOT justify a switch

Several common reasons patients switch to NDT do not hold up to scrutiny [C1][C4]:

• "My TSH is normal but I still feel bad" without checking ferritin, vitamin D, B12, sleep, mood, or other reversible causes. Most residual symptoms on adequate levothyroxine have non-thyroid contributors that NDT will not fix [C1][C7].
• "I want a more natural option." "Natural" does not mean physiologic. The T3 dose in NDT is supraphysiologic relative to what a healthy thyroid releases [C1][C4].
• "Reverse T3 is high." Reverse T3 is a marker of acute illness or caloric restriction, not a treatment target. The ATA does not recommend treating reverse T3 [C1].
• "My free T3 is low-normal." Free T3 in the low-normal range with normal TSH is not, by itself, an indication for NDT [C1][C4].

Practical guidelines

1. Levothyroxine first. The ATA recommends levothyroxine monotherapy as first-line for hypothyroidism. Most patients reach symptom resolution on it once TSH is stable in the normal range and reversible contributors (iron, vitamin D, B12, sleep, mood) are addressed [C1][C7].
2. Confirm persistent symptoms are thyroid-driven before switching. Your endocrinologist will recheck TSH, free T4, and free T3, and screen for non-thyroid contributors before considering NDT [C1][C4].
3. If a trial of NDT is agreed, monitor closely. TSH, free T4, and free T3 at 6 to 8 weeks after starting and after every dose change. Free T3 timing matters — draw before the next dose, not at peak [C1][C4].
4. Avoid TSH suppression. Persistently suppressed TSH (below 0.1 mIU/L) raises cardiac and bone risk on any thyroid hormone preparation [C1][C5][C6].
5. Set a stop rule. A typical NDT trial runs 3 to 6 months with predefined symptom and lab criteria. If no benefit, return to levothyroxine [C4].
6. Switch to levothyroxine in pregnancy. Anyone planning pregnancy or who becomes pregnant on NDT is transitioned to levothyroxine [C1][C7].

Frequently asked questions

Is NDT better than levothyroxine? Randomized trials have not shown a consistent advantage on objective outcomes. Patient preference surveys are split — some prefer NDT, some prefer levothyroxine, many have no preference [C2][C3][C4].

Will NDT cure my Hashimoto's? No. No thyroid hormone preparation cures Hashimoto's. The autoimmune process continues regardless of which replacement is used. Treatment replaces the missing hormone — it does not stop the gland from being attacked [C1].

Is NDT more "natural" than levothyroxine? The hormone in levothyroxine tablets is structurally identical to the T4 your own thyroid makes. NDT is a porcine extract — natural to a pig, not to a human — and delivers a supraphysiologic T3 dose relative to a healthy gland [C1][C4].

Can I switch myself from levothyroxine to NDT? Switching without supervision is unsafe. The conversion ratio is approximate, T3 absorption is faster than T4, and TSH and cardiac monitoring are required. Your endocrinologist will manage the transition and lab schedule [C1][C4].

What about T3-only therapy? T3-only therapy (liothyronine alone) is not recommended outside very specific circumstances and carries higher cardiac and bone risk than levothyroxine [C5]. See our liothyronine-t3-only article.

Bottom line

Natural desiccated thyroid (Armour, NP Thyroid) is a porcine extract with a fixed T4:T3 ratio of about 4:1 [C1][C4]. Randomized trials show no consistent advantage over levothyroxine on objective outcomes, although a subset of patients reports a preference for it [C2][C3]. The American Thyroid Association recommends levothyroxine as first-line and reserves NDT or combination therapy for selected patients who remain symptomatic on adequate monotherapy after reversible contributors are ruled out [C1][C4]. The main safety concern is the supraphysiologic T3 dose, with associated cardiac and bone risks especially when TSH is suppressed [C5][C6]. If a switch is considered, your endocrinologist will run a structured trial with close monitoring and a clear stop rule [C4].